EGFR and neoplasm: The case series reported in this article aim to illustrate the clinical relevance of RAS mutations identified in ctDNA samples of patients with mCRC with a baseline RAS wild-type tumor tissue and who received an anti-EGFR monoclonal antibody plus chemotherapy as first-line treatment.